Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name	of entity Kazia Therapeutics Limited ("Kazia")	
ABN	37 063 259 754	

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr James Garner
Date of last notice	13 November 2019

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct	
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.		
Date of change	2 December 2019	
No. of securities held prior to change	120,000 ordinary shares Commitment to purchase 65,000 ordinary shares Total interest: 185,000 shares 1,200,000 unlisted options	
Class	Ordinary shares	
Number acquired	65,000 ordinary shares – the commitment to purchase these shares was announced on 3 July 2019. The shares have now been transferred.	

⁺ See chapter 19 for defined terms.

Appendix 3Y Change of Director's Interest Notice

Number disposed	N/A	
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	65,000 ordinary shares at 33.087c per share	
No. of securities held after change	185,000 ordinary shares	
	1,200,000 unlisted options	
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Off market trade	

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	

Appendix 3Y Page 2 01/01/2011

⁺ See chapter 19 for defined terms.

No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – *Closed period

Were the interests in the securities or contracts detailed above	Yes
traded during a ⁺ closed period where prior written clearance was required?	
If so, was prior written clearance provided to allow the trade to proceed during this period?	Yes
If prior written clearance was provided, on what date was this provided?	3 July 2019

⁺ See chapter 19 for defined terms.